Treatment of Aggressive Localized Lymphoma

• Status: Terminated
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma , age 18 to 75 years.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Treatments: Doxorubicin; Liposomal doxorubicin; Prednisone; Rituximab; Vincristine

Criteria

Inclusion Criteria:

• Age > 18 and < 75 years

• Diffuse B large cell lymphoma , CD 20+

• Ann Arbor stage I or II withe a bulk <7 cm

• stage i ou II confirmed by the PET-scan

• No previously treated

• HIV negative

• Signed Informed consent

Exclusion Criteria:

• Age< 18 and > 75 years

• other type of lymphoma

• CD20 negative

• Ann Arbor stage >II or bulk > 7 cm

• HIV positive

• Contraindication to Rituximab use according to Sm PC

• Containdication to antracyclin

• cancer or history of cancer , excepted in situ cancer of the cervix or skin epithelioma

• Refusal of sign the informed consent